Device-Based Therapy for Hypertension: New Frontiers in Patient Care
“If you think about hypertension, it’s a global healthcare crisis,” said Eso. “Half of this auditorium probably has it. It’s bigger than diabetes, bigger than many other diseases from a cardiovascular perspective.” Eso traced Medtronic’s entry into hypertension therapeutics back to its 2009 investment in Ardian, the pioneer behind renal denervation devices. At the time, hypertension management was still viewed almost exclusively through a pharmaceutical lens. Devices weren’t yet considered part of the solution. However, early clinical learnings revealed significant gaps that medication alone couldn’t fill — particularly in adherence. To read more about visit here: https://anyflip.com/ybicl/xonm/basic